

MAY 21 2003
PATENT & TRADEMARK OFFICE

AMENDMENT TO THE CLAIMS

1. (currently amended) An isolated peptide selected from the group consisting of
comprising:

(X1)_nEVEKIKTTVKESATEEKLTPVX2L(X23)_m (SEQ ID NO: 1),

(Y1)_nEVAALQVDRKVADEEKQSYDAV(Y2)_m (SEQ ID NO: 2),

wherein

n and m independently represents 0 or 1;

X1, X2 and X3 are independently defined as follows

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or

VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or

KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5), or

ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6), or

TPQQKYQRLLHEVQELTT (SEQ ID NO: 7), or

PQQKYQRLLHEVQELTT (SEQ ID NO: 8), or

QQKYQRLLHEVQELTT (SEQ ID NO: 9), or

QKYQRLLHEVQELTT (SEQ ID NO: 10), or

KYQRLLHEVQELTT (SEQ ID NO: 11), or

YQRLLHEVQELTT (SEQ ID NO: 12), or

QRLLHEVQELTT (SEQ ID NO: 13), or

RLHEVQELTT (SEQ ID NO: 14), or

LLHEVQELTT (SEQ ID NO: 15), or

LHEVQELTT (SEQ ID NO: 16), or

HEVQELTT (SEQ ID NO: 17), or

EVQELTT (SEQ ID NO: 18), or

VQELTT (SEQ ID NO: 19), or

QELTT (SEQ ID NO: 20), or

ELTT (SEQ ID NO: 21), or

LTT, or

TT, or

T;

X2 is V or L, and

X3 is AKQLAAL (SEQ ID NO: 22), or

AKQLAA (SEQ ID NO: 23), or

RECEIVED

MAY 28 2003

TECH CENTER 1600/2900

E1

AKQLA (SEQ ID NO: 24), or
AKQL (SEQ ID NO: 25), or
AKQ, or
AK, or
A;

and

Y1 and Y2 are independently defined as follows

Y1 is ~~GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or~~
~~EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or~~
~~KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or~~
~~ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or~~
~~TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or~~
~~PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or~~
~~VQKCQRLQIEMNELLN (SEQ ID NO: 32), or~~
~~QKCQRLQIEMNELLN (SEQ ID NO: 33), or~~
~~KCQRLQIEMNELLN (SEQ ID NO: 34), or~~
~~CQRLQIEMNELLN (SEQ ID NO: 35), or~~
~~QRLQIEMNELLN (SEQ ID NO: 36), or~~
~~RLQIENINELLN (SEQ ID NO: 37), or~~
~~LQIEMNELLN (SEQ ID NO: 38), or~~
~~QIEMNELLN (SEQ ID NO: 39), or~~
~~IENINELLN (SEQ ID NO: 40), or~~
~~EMNELLN (SEQ ID NO: 41), or~~
~~MNELLN (SEQ ID NO: 42), or~~
~~NELLN (SEQ ID NO: 43), or~~
~~ELLN (SEQ ID NO: 44), or~~
~~LLN, or~~
~~LN, or~~
~~N; and~~

Y2 is ~~VATVISTAR (SEQ ID NO: 45), or~~
~~VATVISTA (SEQ ID NO: 46), or~~
~~VATVIST (SEQ ID NO: 47), or~~
~~VATVIS (SEQ ID NO: 48), or~~

~~VATVI (SEQ ID NO: 49), or~~

~~VATV (SEQ ID NO: 50), or~~

~~VAT, or~~

~~VA, or~~

~~V, and~~

~~derivatives a fragment thereof or a derivative thereof having at least about 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2.~~

2. (original) The peptide of claim 1 which is
GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVX2LAKQLAAL
(SEQ ID NO: 51),
wherein X2 is as defined in claim 1.

3. (original) The peptide of claim 1 which is
GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR (SEQ
ID NO: 52).

4-8. (canceled)

9. (original) The peptide of claim 1 capable of modulating cellular
proliferation.

10. (original) The peptide of claim 1 capable of inhibiting cellular proliferation.

11. (original) The peptide of claim 10 capable of selective inhibition of
cancerous cells.

12-14. (canceled)

15. (original) A composition comprising a peptide of claim 1 in admixture with
a pharmaceutically acceptable carrier.

16. (canceled)

17. (original) A method for inhibiting cellular proliferation comprising delivering to a target cell an effective amount of an isolated peptide of claim 1 or a nucleic acid encoding said peptide.

18-20 (canceled)

E1 21. (original) The method of claim 17 wherein said target cell is a tumor cell.

22. (original) The method of claim 21 wherein said tumor cell is a cancer cell.

23-27. (canceled)
